바이오사이토젠은 환자의 수요를 만족시키는 혁신적인 항체 신약 개발을 위하여, 항암, 자가면역질환, 대사질환, 감염질환 등의 다양한 질병 영역에서 독자적이며 혁신적인 신약개발 능력을 활용하여 단일클론항체, 이중특이성항체, ADC 등을 포함한 십여개의 연구개발중인 파이프라인을 보유하고 있습니다. 강력한 임상개발팀과 풍부한 임상자원을 바탕으로, 잠재력있는 파이프라인의 개발을 가속화하여 신약의 임상 개발 과정을 앞당기고 있습니다.
Solid tumor + Hematological malignancy
More
Inflammation and Autoimmunity
Oncology
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Indication:
Solid tumor + Hematological malignancy
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Partner:
Chipscreen NewWay
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Inflammation and Autoimmunity
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Infectious Diseases
Indication:
Infectious Diseases
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Rare Diseases
Indication:
Rare diseases
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA